{"id":"paclitaxel-gemcitabine-admixture","safety":{"commonSideEffects":[{"rate":"40–60%","effect":"Neutropenia"},{"rate":"20–40%","effect":"Anemia"},{"rate":"20–40%","effect":"Thrombocytopenia"},{"rate":"15–30%","effect":"Peripheral neuropathy"},{"rate":"30–50%","effect":"Nausea/vomiting"},{"rate":"30–50%","effect":"Fatigue"},{"rate":"20–40%","effect":"Alopecia"},{"rate":"10–20%","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL3039516","moleculeType":"Small molecule","molecularWeight":"527.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, halting mitosis. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and is incorporated into DNA, causing chain termination. The combination exploits complementary mechanisms to enhance cytotoxicity against rapidly dividing cells.","oneSentence":"This combination uses paclitaxel to stabilize microtubules and gemcitabine to inhibit ribonucleotide reductase, together disrupting cell division and DNA synthesis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:50.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Breast cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT03085004","phase":"PHASE3","title":"CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2019-04-12","conditions":"Pancreatic Cyst, EUS-FNA","enrollment":75},{"nctId":"NCT01475331","phase":"PHASE2","title":"The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2011-11","conditions":"Mucinous Pancreatic Cysts","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel + Gemcitabine admixture","genericName":"Paclitaxel + Gemcitabine admixture","companyName":"Milton S. Hershey Medical Center","companyId":"milton-s-hershey-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses paclitaxel to stabilize microtubules and gemcitabine to inhibit ribonucleotide reductase, together disrupting cell division and DNA synthesis in cancer cells. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}